Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Merck
Boehringer Ingelheim
McKesson
Colorcon
Express Scripts

Last Updated: August 19, 2022

ADHANSIA XR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Adhansia Xr, and what generic alternatives are available?

Adhansia Xr is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are twelve patents protecting this drug.

This drug has thirty patent family members in seventeen countries.

The generic ingredient in ADHANSIA XR is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

Summary for ADHANSIA XR
International Patents:30
US Patents:12
Applicants:1
NDAs:1
Clinical Trials: 2
Formulation / Manufacturing:see details
Drug Prices: Drug price information for ADHANSIA XR
What excipients (inactive ingredients) are in ADHANSIA XR?ADHANSIA XR excipients list
DailyMed Link:ADHANSIA XR at DailyMed
Drug patent expirations by year for ADHANSIA XR
Drug Prices for ADHANSIA XR

See drug prices for ADHANSIA XR

Recent Clinical Trials for ADHANSIA XR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Purdue Pharma LPPhase 4

See all ADHANSIA XR clinical trials

US Patents and Regulatory Information for ADHANSIA XR

ADHANSIA XR is protected by twelve US patents and two FDA Regulatory Exclusivities.

Patents protecting ADHANSIA XR

Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

Methods and compositions particularly for treatment of attention deficit disorder
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting ADHANSIA XR

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

LABELING REVISIONS RELATED TO CLINICAL STUDIES
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-006 Feb 27, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-003 Feb 27, 2019 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-003 Feb 27, 2019 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Purdue Pharma Lp ADHANSIA XR methylphenidate hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 212038-004 Feb 27, 2019 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ADHANSIA XR

See the table below for patents covering ADHANSIA XR around the world.

Country Patent Number Title Estimated Expiration
Japan 2017532363 特に注意欠陥障害の治療のための方法および組成物 See Plans and Pricing
Eurasian Patent Organization 201790950 СПОСОБЫ И КОМПОЗИЦИИ, В ЧАСТНОСТИ, ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ДЕФИЦИТА ВНИМАНИЯ See Plans and Pricing
Canada 2936741 METHODES ET COMPOSITIONS DESTINEES AU TRAITEMENT DU TROUBLE DE DEFICIT D'ATTENTION (METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER) See Plans and Pricing
Canada 2936746 METHODES ET COMPOSITIONS DESTINEES AU TRAITEMENT DU TROUBLE DE DEFICIT D'ATTENTION (METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.